Anales RANF

Vanesa Nozal, Alfonso García-Rubia, Concepción Pérez, Ana Martínez, Valle Palomo @Real Academia Nacional de Farmacia. Spain 272 6. AGRADECIMIENTOS Este trabajo ha sido financiado por el MINECO (SAF2016-76693-R). V.N. poseee un contrato pre-doctoral FPU (FPU16/04466). V.P. quiere agradecer a la Caixa por su beca Junior Leader. 7. REFERENCIAS 1. Ramsay RR, Popovic-Nikolic MR, Nikolic K, Uliassi E, Bolognesi ML. A perspective on multi-target drug discovery and design for complex diseases. Clin. Transl. Med. 2018; 7: 3. 2. Rutherford GW, Sangani PR, Kennedy GE. Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection. Cochrane Database Syst. Rev.4. 2003. Frishman WH, Zuckerman AL. Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Expert Rev. Cardiovasc. Ther. 2004; 2(5), 675–681. 3. Cavalli A, Bolognesi ML, Minarini A, Rosini M, Tumiatti V, Recanatini M, Melchiorre C. Multi- target-Directed Ligands To Combat Neurodegenerative Diseases. J. Med. Chem. 2008; 51: 347–372 4. Van der Schyf CJ. The use of multi-target drugs in the treatment of neurodegenerative diseases, Expert. Rev. Clin. Pharmacol., 2011;4:3, 293-298, 5. Bachurin SO, Bovina EV, Ustyugov AA. Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends. Med. Res. Rev. 2017; 37: 1186-1225. 6. Bottegoni G, Favia AD, Recanatini M, Cavalli A. The role of fragment-based and computational methods in polypharmacology. Drug Discov Today. 2012;17: 23– 34. 7. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol Med. 2016; 8:(6), 595-608. 8. Martin L, Latypovac X, Wilsona CM, Magnaudeixa A, Perrina ML, Yardina C, Terroa F. Tau protein kinases: Involvement in Alzheimer’s disease. Ageing Res Rev. 2013; 12: 289-309. 9. Bailey, R.M.; Covy, J.P.; Melrose, H.L.; Rouseau, L.; Watkinson, R.; Knoght, J.; Miles, S.; Farrer, M. J.; Dickson, D.W.; Giasson, B. I.; Lewis, J., LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol 2013; 126: (6), 809-827. 10. Savelieff MG, Nam G, Kang J, Lee HJ, Lee M, Lim MH. Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis in the Last Decade. Chem Rev. 2018; Aug 10. doi: 10.1021/acs.chemrev.8b00138. 11. Morales-Garcia, J.; Salado, I. G.; Sanz-San Cristobal, M.; Gil, C.; Pérez-Castillo, A.; Martínez, A.; Pérez, D. I. Biological and pharmacological characterization of Benzothiazole based CK-1 δ inhibitors in models of Parkinson’s disease. ACS Omega 2017; 2: 5215-5220. 12. Palomo, V.; Perez, D. I.; Perez, C.; Morales-Garcia, J. A.; Soteras, I.; Alonso-Gil, S.; Encinas, A.; Castro, A.; Campillo, N. E.; Perez-Castillo, A.; Gil, C.; Martinez, A. 5-Imino-1,2,4-thiadiazoles: first small molecules as substrate competitive inhibitors of glycogen synthase kinase 3. J. Med. Chem. 2012; 55: 1645-1661 13. Sebastián-Pérez, V.; Roca, C.; Awale, M.; Reymond, J. L.; Martínez, A.; Gil, C.; Campillo, N. E. The Medicinal and Biological Chemistry (MBC) library: an efficient source on new hits. J. Chem. Inf. Model. 2017; 57: 2143-2151 14. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999; 286: 735-41. 15. Nishitomi K, Sakaguchi G, Horikoshi Y, Gray AJ, Maeda M, Hirata-Fukae C, Becker AG, Hosono M, Sakaguchi I, Minami SS, Nakajima Y, Li HF, Takeyama C, Kihara T, Ota A, Wong PC, Aisen PS, Kato A, Kinoshita N, Matsuoka Y. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. J Neurochem. 2006; 99:1555-63. 16. Morales-Garcia, J.; Salado, I. G.; Sanz-San Cristobal, M.; Gil, C.; Pérez-Castillo, A.; Martínez, A.; Pérez, D. I. Biological and pharmacological characterization of Benzothiazole based CK-1 δ inhibitors in models of Parkinson’s disease. ACS Omega 2017; 2: 5215-5220. 17. Palomo, V.; Martinez, A. Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015). Expert Opin. Ther. Pat. 2017; 27: 657-666. 18. Mohammed I, Kummetha IR, Singh G, Sharova N, Lichinchi G, Dang J, Stevenson M, Rana TM. 1,2,3- Triazoles as Amide Bioisosteres: Discovery of a New Class of Potent HIV-1 Vif Antagonists J Med Chem. 2016;59(16):7677-82. 19. Kolb HC1, Sharpless KB The growing impact of click chemistry on drug discovery. Drug Discov Today. 2003; 8:(24), 1128-37 20. Martinez A, Alonso M, Castro A, Pérez C, Moreno FJ. First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3 β ) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease. J. Med. Chem. 2002; 45: 1292- 1299. 21. Salado IG, Zaldivar-Diez J, Sebastián-Pérez V, Li L, Geiger L, González S, Campillo NE, Gil C, Morales AV, Perez DI, Martinez A. Leucine rich repeat kinase 2 (LRRK2) inhibitors based on indolinone scaffold: Potential pro-neurogenic agents. Eur J Med Chem. 2017; 138: 328-342. 22. Salado IG, Redondo M, Bello ML, Perez C, Liachko NF, Kraemer BC, Miguel L, Lecourtois M, Gil C, Martinez A, Perez DI. Protein kinase CK-1 inhibitors